Ted-Stephens-300x300
Gynesonics Announces Key Executive Appointments to Further Accelerate and Expand Adoption of the Sonata Treatment
March 19, 2024 10:00 ET | Gynesonics
Gynesonics announces key executive appointments to further accelerate and expand adoption of the Sonata Treatment.
Gynesonics Logo.jpg
Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids
January 02, 2024 11:13 ET | Gynesonics
Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids
Gynesonics Logo.jpg
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
November 02, 2023 09:41 ET | Gynesonics
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
Gynesonics Logo.jpg
CORRECTION – Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
November 01, 2023 20:08 ET | Gynesonics
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
Gynesonics Logo.jpg
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
November 01, 2023 16:00 ET | Gynesonics
Gynesonics Announces $67M Financing to Expand Commercialization of Sonata® Procedure
Gynesonics Logo.jpg
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally
October 25, 2023 16:07 ET | Gynesonics
Gynesonics is pleased to announce that its Sonata Procedure has been used to treat over 1,000 women in the United States in 2023
Gynesonics Logo.jpg
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally
October 17, 2023 12:00 ET | Gynesonics
Gynesonics' Sonata® Procedure has been used to treat over 1,000 women in the United States and approximately 6,500 women globally.
Skip Baldino
Gynesonics Names Industry Veteran Skip Baldino President and CEO, Announces $25M Financing to Expand Worldwide Commercialization
April 11, 2023 12:00 ET | Gynesonics
REDWOOD CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids,...
Featured Image for The Fibroid Foundation
The Fibroid Foundation Announces Fibroid Awareness Month 2022
July 06, 2022 15:30 ET | The Fibroid Foundation
WASHINGTON, July 06, 2022 (GLOBE NEWSWIRE) -- The Fibroid Foundation announces the Fibroid Awareness Month event schedule for July 2022. This Year's Fibroid Awareness Month Theme is 'Real...
Obseva Logo highresolution.jpg
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
June 28, 2022 16:01 ET | ObsEva SA
  -Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to...